THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 98 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2019. The put-call ratio across all filers is 6.05 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $242,805 | -2.2% | 28,135 | +17.2% | 0.00% | – |
| Q2 2023 | $248,369 | -52.2% | 23,997 | -49.9% | 0.00% | – |
| Q1 2023 | $519,585 | +10.4% | 47,888 | +14.1% | 0.00% | – |
| Q4 2022 | $470,780 | +54.4% | 41,959 | +39.6% | 0.00% | – |
| Q3 2022 | $305,000 | -17.1% | 30,063 | -25.9% | 0.00% | – |
| Q2 2022 | $368,000 | -9.4% | 40,574 | -4.2% | 0.00% | – |
| Q1 2022 | $406,000 | -19.9% | 42,366 | -7.6% | 0.00% | – |
| Q4 2021 | $507,000 | +70.7% | 45,869 | +14.4% | 0.00% | – |
| Q3 2021 | $297,000 | -45.1% | 40,101 | +7.7% | 0.00% | – |
| Q2 2021 | $541,000 | -87.0% | 37,238 | -81.8% | 0.00% | -100.0% |
| Q1 2021 | $4,170,000 | +9.2% | 204,286 | -5.0% | 0.00% | 0.0% |
| Q4 2020 | $3,819,000 | -1.3% | 214,971 | -17.9% | 0.00% | -33.3% |
| Q3 2020 | $3,870,000 | -61.8% | 261,742 | -45.7% | 0.00% | -62.5% |
| Q2 2020 | $10,118,000 | -8.1% | 482,021 | +1.2% | 0.01% | -20.0% |
| Q1 2020 | $11,010,000 | +929.0% | 476,386 | +1049.4% | 0.01% | +900.0% |
| Q4 2019 | $1,070,000 | +328.0% | 41,448 | +220.6% | 0.00% | – |
| Q3 2019 | $250,000 | -43.9% | 12,929 | -52.9% | 0.00% | – |
| Q2 2019 | $446,000 | -65.0% | 27,443 | -51.3% | 0.00% | -100.0% |
| Q1 2019 | $1,276,000 | -4.6% | 56,394 | +7.6% | 0.00% | 0.0% |
| Q4 2018 | $1,338,000 | -88.7% | 52,394 | -85.5% | 0.00% | -66.7% |
| Q3 2018 | $11,830,000 | +137.5% | 362,203 | +64.8% | 0.00% | +200.0% |
| Q2 2018 | $4,982,000 | +88.1% | 219,747 | +101.1% | 0.00% | 0.0% |
| Q1 2018 | $2,648,000 | -12.6% | 109,295 | +0.5% | 0.00% | -50.0% |
| Q4 2017 | $3,031,000 | +48.7% | 108,750 | +82.4% | 0.00% | +100.0% |
| Q3 2017 | $2,038,000 | -12.1% | 59,613 | +2.3% | 0.00% | -50.0% |
| Q2 2017 | $2,318,000 | +236.9% | 58,276 | +211.3% | 0.00% | +100.0% |
| Q1 2017 | $688,000 | -72.5% | 18,718 | -76.2% | 0.00% | -50.0% |
| Q4 2016 | $2,506,000 | +44.4% | 78,707 | +64.2% | 0.00% | +100.0% |
| Q3 2016 | $1,735,000 | +61.2% | 47,939 | +0.7% | 0.00% | 0.0% |
| Q2 2016 | $1,076,000 | +42.3% | 47,610 | +17.9% | 0.00% | 0.0% |
| Q1 2016 | $756,000 | +61.9% | 40,392 | +40.6% | 0.00% | – |
| Q4 2015 | $467,000 | +96.2% | 28,725 | +31.4% | 0.00% | – |
| Q3 2015 | $238,000 | -92.4% | 21,862 | -90.9% | 0.00% | -100.0% |
| Q2 2015 | $3,143,000 | +841.0% | 241,553 | +1143.8% | 0.00% | – |
| Q1 2015 | $334,000 | -91.9% | 19,420 | -93.0% | 0.00% | -100.0% |
| Q4 2014 | $4,148,000 | +79.8% | 278,209 | +177.8% | 0.00% | +200.0% |
| Q3 2014 | $2,307,000 | -46.0% | 100,141 | -25.3% | 0.00% | -66.7% |
| Q2 2014 | $4,269,000 | – | 133,992 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,269,584 | $69,497,223,000 | 12.98% |
| Newtyn Management, LLC | 1,375,000 | $13,145,000 | 3.15% |
| Chescapmanager LLC | 1,166,574 | $11,152,000 | 1.51% |
| Baupost Group | 13,643,333 | $130,430,000 | 1.40% |
| Weiss Asset Management LP | 5,412,487 | $51,743,000 | 1.07% |
| CM Management, LLC | 120,000 | $1,147,000 | 0.96% |
| Orbimed Advisors | 3,254,713 | $31,115,000 | 0.50% |
| King Wealth Management Group | 122,000 | $1,166,000 | 0.23% |
| Woodline Partners LP | 1,326,653 | $12,683,000 | 0.21% |
| PDT Partners, LLC | 192,701 | $1,842,000 | 0.16% |